Re: Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer.
Tanvetyanon
Tawee
T
D001859:Bone Neoplasms / Q000517:prevention & control* / Q000556:secondary; D003362:Cost-Benefit Analysis; D004164:Diphosphonates / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000191:economics* / Q000627:therapeutic use; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology; D000077211:Zoledronic Acid
D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid